Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
ABUS

ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

3.06USD+0.11 (+3.73%)Market Closed

Market Summary

ABUS
USD3.06+0.11
Market Closed
3.73%

ABUS Stock Price

View Fullscreen

ABUS RSI Chart

ABUS Valuation

Market Cap

577.5M

Price/Earnings (Trailing)

-7.76

Price/Sales (Trailing)

44.47

EV/EBITDA

-6.67

Price/Free Cashflow

-7.32

ABUS Price/Sales (Trailing)

ABUS Profitability

EBT Margin

-547.54%

Return on Equity

-64.89%

Return on Assets

-49.49%

Free Cashflow Yield

-13.67%

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

13.0M

Rev. Growth (Yr)

-77.09%

Rev. Growth (Qtr)

-28.58%

ABUS Earnings

Earnings (TTM)

-74.4M

Earnings Growth (Yr)

-9.4%

Earnings Growth (Qtr)

7.44%

Breaking Down ABUS Revenue

Last 7 days

-2.5%

Last 30 days

-10.3%

Last 90 days

22.4%

Trailing 12 Months

23.9%

How does ABUS drawdown profile look like?

ABUS Financial Health

Current Ratio

6.69

ABUS Investor Care

Shares Dilution (1Y)

13.59%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202413.0M000
202333.1M23.5M22.2M18.1M
202221.5M33.4M36.0M39.0M
20217.5M8.4M10.2M11.0M
20206.2M6.5M6.7M6.9M
20195.2M4.6M9.5M6.0M
201811.9M12.1M6.8M5.9M
20173.8M6.1M8.4M10.7M
201619.0M13.2M7.3M1.5M
201515.2M16.8M16.5M24.9M
201417.8M16.7M18.1M15.0M
201317.9M17.1M16.3M15.5M
201217.1M17.5M17.9M18.3M
201120.2M19.0M17.8M16.6M
201000021.4M
200900014.4M

Tracking the Latest Insider Buys and Sells of Arbutus Biopharma Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 02, 2024
sims karen
sold
-10,077
2.3125
-4,358
chief medical officer
Feb 02, 2024
mcelhaugh michael j.
sold
-23,504
2.3125
-10,164
interim president & ceo
Feb 02, 2024
sofia michael j.
sold
-23,083
2.3125
-9,982
chief scientific officer
Feb 02, 2024
hastings david c
sold
-22,183
2.3125
-9,593
chief financial officer
Feb 01, 2024
sims karen
acquired
-
-
101,000
chief medical officer
Feb 01, 2024
mcelhaugh michael j.
acquired
-
-
123,800
interim president & ceo
Feb 01, 2024
sofia michael j.
acquired
-
-
109,500
chief scientific officer
Feb 01, 2024
naftzger j. christopher
acquired
-
-
95,100
general counsel and cco
Feb 01, 2024
hastings david c
acquired
-
-
112,500
chief financial officer
Feb 01, 2023
collier william h.
acquired
-
-
216,500
president and ceo

1–10 of 19

Which funds bought or sold ABUS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 30, 2024
CAMBRIDGE TRUST CO
unchanged
-
400
12,900
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
66.15
34,161
83,161
0.01%
May 20, 2024
Virtu Financial LLC
sold off
-100
-45,000
-
-%
May 16, 2024
Arete Wealth Advisors, LLC
sold off
-100
-37,500
-
-%
May 16, 2024
FourWorld Capital Management LLC
added
175
5,014,230
7,741,360
4.94%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-19,274
32,861
-%
May 16, 2024
Tidal Investments LLC
new
-
111,340
111,340
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-54.29
-127,445
113,827
-%
May 15, 2024
Steward Partners Investment Advisory, LLC
unchanged
-
320
10,320
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
reduced
-84.25
-3,219,900
624,907
-%

1–10 of 42

Are Funds Buying or Selling ABUS?

Are funds buying ABUS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABUS
No. of Funds

Unveiling Arbutus Biopharma Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 10, 2024
morgan stanley
10.3%
19,392,488
SC 13G
May 17, 2024
whitefort capital management, lp
6.8%
12,867,967
SC 13D/A
May 09, 2024
whitefort capital management, lp
6.8%
12,867,967
SC 13D
Feb 14, 2024
two seas capital lp
5.4%
9,041,927
SC 13G/A
Feb 14, 2024
whitefort capital management, lp
7.9%
13,197,062
SC 13G/A
Feb 12, 2024
blackrock inc.
6.2%
10,390,300
SC 13G/A
Nov 21, 2023
two seas capital lp
5.7%
9,503,103
SC 13G
Sep 11, 2023
whitefort capital management, lp
6.0%
10,013,899
SC 13G
Feb 03, 2023
blackrock inc.
5.6%
8,700,392
SC 13G
Feb 14, 2022
rtw investments, lp
1.7%
2,504,493
SC 13G/A

Recent SEC filings of Arbutus Biopharma Corp

View All Filings
Date Filed Form Type Document
Jun 10, 2024
SC 13G
Major Ownership Report
Jun 06, 2024
8-K
Current Report
Jun 05, 2024
8-K
Current Report
May 28, 2024
8-K
Current Report
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading
May 24, 2024
4
Insider Trading

Peers (Alternatives to Arbutus Biopharma Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.9B
2.0B
9.73% -16.82%
-63.08
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.45
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.36
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.81
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.26
14.48
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.7
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Arbutus Biopharma Corp News

Latest updates
Yahoo Canada Shine On20 Jun 202401:25 pm
Defense World18 Jun 202406:53 am
Defense World06 Jun 202407:00 am

Arbutus Biopharma Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-28.6%1,532,0002,145,0004,658,0004,651,0006,687,0006,245,0005,952,00014,241,00012,581,0003,206,0003,340,0002,329,0002,113,0002,386,0001,523,0001,514,0001,491,0003,988,5006,486,000653,000679,000
Operating Expenses-8.7%20,895,00022,892,00026,216,00023,036,00024,100,00028,807,00023,763,00028,350,00023,555,00024,002,00021,748,00020,971,00017,789,00018,687,00016,740,00014,655,00014,638,00014,653,00094,086,00021,298,00019,875,000
  S&GA Expenses4.1%5,312,0005,101,0005,842,0005,980,0005,552,0004,249,0003,493,0005,200,0004,892,0004,597,0004,183,0004,478,0003,878,0003,661,0004,065,0003,566,0003,553,0001,877,0003,249,0008,189,0004,412,000
  R&D Expenses-12.3%15,403,00017,564,00020,169,00017,692,00018,275,00022,949,00020,055,00022,942,00018,462,00019,212,00016,709,00015,799,00013,782,00016,392,00012,065,00010,465,00010,416,00012,418,00017,731,00012,740,00014,712,000
EBITDA Margin-40.0%-5.34-3.82-3.10-2.67-1.71-1.51-1.63-1.80-2.89-6.13-6.60-7.94---------
Interest Expenses0%44,00044,00046,000171,000198,000309,000429,000482,000506,000560,000762,000763,000772,000797,0001,074,0001,099,0001,041,000994,0001,100,0002,00012,000
Income Taxes---------4,444,000----------12,656,000--
Earnings Before Taxes----20,104,000-17,094,000-16,339,000--17,567,000-14,192,000-11,321,000--19,158,000-19,387,000-16,381,000-17,042,000-18,755,000-14,087,000-13,861,000-24,654,000-95,159,000-23,315,000-23,251,000
EBT Margin-39.7%-5.48-3.92-3.20-2.77-1.79-1.60-1.73-1.92-3.09-6.55-7.08-8.57---------
Net Income7.4%-17,875,000-19,312,000-20,104,000-17,094,000-16,339,000-21,932,000-17,567,000-14,192,000-15,765,000-21,321,000-19,158,000-19,387,000-16,381,000-17,042,000-18,755,000-14,087,000-13,861,000-24,654,000-82,503,000-23,315,000-23,251,000
Net Income Margin-42.6%-5.73-4.02-3.39-3.10-2.11-1.78-1.91-2.11-3.52-6.94-7.08-8.57---------
Free Cashflow-12.1%-19,390,000-17,292,000-21,816,000-20,418,000-27,418,000-17,124,000-18,783,000-20,505,00020,544,000-19,664,000-16,056,000-14,641,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets4.1%15014415917719119520421623720416613514613713198.00103106117193209
  Current Assets2.9%13613214215915315114115817316112783.0013712812186.0088.0094.0094.00100112
    Cash Equivalents64.0%43.0026.0018.0027.0041.0031.0024.0047.0081.0010978.0031.0079.0052.0097.0046.0026.0032.0090.0079.0084.00
  Net PPE-5.6%4.005.005.005.005.005.005.005.006.006.006.007.007.007.007.008.008.009.009.009.0010.00
  Goodwill--------------------22.0022.00
Liabilities-7.1%36.0038.0039.0042.0047.0059.0058.0063.0071.0035.0035.0035.0032.0035.0034.0032.0029.0033.0034.0028.0028.00
  Current Liabilities-9.7%20.0022.0022.0025.0025.0033.0028.0030.0032.0011.0010.009.007.0010.008.006.004.008.009.009.009.00
Shareholder's Equity8.1%11510611913514413714615316616913010111410297.0066.0073.0073.0084.00164181
  Retained Earnings-1.4%-1,294-1,276-1,257-1,237-1,220-1,203-1,181-1,164-1,150-1,134-1,112-1,088-1,065-1,045-1,025-1,004-986-970-942-857-831
  Additional Paid-In Capital-1.3%80.0081.0080.0077.0074.0072.0071.0069.0067.0065.0064.0064.0062.0061.0060.0058.0057.0055.0055.0054.0050.00
Accumulated Depreciation3.0%12.0012.0012.0011.0011.0011.0010.0010.0010.009.009.008.008.008.007.007.009.006.009.008.007.00
Shares Outstanding6.1%18017016816716215715114914814510197.00---------
Float----288---290---238---130---118-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-11.6%-19,295-17,292-21,784-19,559-27,301-16,990-18,692-20,29320,619-19,606-16,036-14,009-17,881-15,013-12,174-8,801-15,453-13,351-23,470-17,605-16,580
  Share Based Compensation16.9%2,0141,7232,4832,9642,1311,6671,7152,0641,7361,4311,6151,7431,6351,4311,6881,5971,445-23.001,5163,7841,522
Cashflow From Investing-47.4%11,69422,22510,4291,44116,67812,682-13,738-13,830-60,056-8,12115,969-38,74718,221-49,97614,09723,371-2,401-58,82216,1559,97261,033
Cashflow From Financing541.7%24,4303,8071,6814,74220,41711,0849,13211311,48559,12146,9524,28926,87420,21049,0964,95912,48113,89318,5492,4792,536
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ABUS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue  
Revenues$ 1,532$ 6,687
Operating expenses  
Research and development15,40318,275
General and administrative5,3125,552
Change in fair value of contingent consideration180273
Total operating expenses20,89524,100
Loss from operations(19,363)(17,413)
Interest income1,5451,268
Interest expense(44)(198)
Foreign exchange gain(13)4
Total other income1,4881,074
Net loss$ (17,875)$ (16,339)
Loss per share  
Basic (in USD per share)$ (0.10)$ (0.10)
Diluted (in USD per share)$ (0.10)$ (0.10)
Weighted average number of common shares  
Basic (in shares)175,625,552161,643,404
Diluted (in shares)175,625,552161,643,404
Comprehensive loss  
Unrealized gain on available-for-sale securities$ 50$ 854
Comprehensive loss(17,825)(15,485)
Collaborations and licenses  
Revenue  
Revenues9395,509
Non-cash royalty revenue  
Revenue  
Revenues$ 593$ 1,178

ABUS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 43,101$ 26,285
Investments in marketable short-term securities86,13999,718
Accounts receivable2,1391,776
Prepaid expenses and other current assets4,4934,248
Total current assets135,872132,027
Property and equipment, net of accumulated depreciation of $12,256 (December 31, 2023: $11,900)4,4144,674
Investments in marketable securities, non-current8,6776,284
Right of use asset1,3271,416
Total assets150,290144,401
Current liabilities:  
Accounts payable and accrued liabilities8,24710,271
Deferred license revenue, current11,54711,791
Lease liability, current502425
Total current liabilities20,29622,487
Liability related to sale of future royalties6,3966,953
Contingent consideration7,7807,600
Lease liability, non-current1,1811,343
Total liabilities35,65338,383
Stockholders’ equity  
Issued and outstanding: 180,192,227 (December 31, 2023: 169,867,414)1,377,3151,349,821
Additional paid-in capital80,22081,270
Deficit(1,294,527)(1,276,652)
Accumulated other comprehensive loss(48,371)(48,421)
Total stockholders’ equity114,637106,018
Total liabilities and stockholders’ equity$ 150,290$ 144,401
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
 CEO
 WEBSITEarbutusbio.com
 INDUSTRYBiotechnology
 EMPLOYEES96

Arbutus Biopharma Corp Frequently Asked Questions


What is the ticker symbol for Arbutus Biopharma Corp? What does ABUS stand for in stocks?

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Arbutus Biopharma Corp (ABUS)?

As of Fri Jun 21 2024, market cap of Arbutus Biopharma Corp is 577.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers.

What is the fair value of ABUS stock?

You can check ABUS's fair value in chart for subscribers. The fair value of Arbutus Biopharma Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Arbutus Biopharma Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Arbutus Biopharma Corp a good stock to buy?

The fair value guage provides a quick view whether ABUS is over valued or under valued. Whether Arbutus Biopharma Corp is cheap or expensive depends on the assumptions which impact Arbutus Biopharma Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABUS.

What is Arbutus Biopharma Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, ABUS's PE ratio (Price to Earnings) is -7.76 and Price to Sales (PS) ratio is 44.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.